D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $31.00 price target on the stock.

A number of other research analysts have also weighed in on NRXP. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a report on Thursday. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP traded down $0.07 during trading on Monday, reaching $2.02. 75,476 shares of the stock were exchanged, compared to its average volume of 451,673. The firm has a market cap of $34.09 million, a price-to-earnings ratio of -0.94 and a beta of 1.22. The stock has a fifty day moving average of $2.82 and a two-hundred day moving average of $2.03. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NRXP. Squarepoint Ops LLC purchased a new position in shares of NRx Pharmaceuticals in the 4th quarter worth about $56,000. Millennium Management LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $61,000. Anson Funds Management LP lifted its stake in NRx Pharmaceuticals by 30.3% in the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after purchasing an additional 43,135 shares during the last quarter. AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after purchasing an additional 180,229 shares during the period. Finally, Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals during the fourth quarter valued at $33,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.